Creatine Kinase during Non-ST-Segment Elevation Acute Coronary Syndromes is Associated with Major Bleeding

Ethical approval

The study protocol was approved by the Review Board of the Research Ethics Committee of the Radboud University Nijmegen Medical Centre on April 30, 2019 (registration number 2019-5356), and by the US National Heart, Lung, and Blood Institute (RMDA V02 1d20120806) on May 6, 2019.

The TIMI 3 trial

Data were used of the Thrombolysis In Myocardial Ischemia Trial 3 (TIMI 3) where CK was routinely estimated during admission in all patients.^9,10 As reported previously,^9,10 the TIMI 3 study consisted of two separate multicenter, randomized controlled double blind clinical trials designed to assess the effects of recombinant tissue plasminogen activator (rt-PA) vs. placebo added to conventional therapy (including intravenous heparin and oral aspirin) on the coronary culprit lesion (TIMI 3A, N=391), and on clinical outcomes (TIMI 3B, N=1473) in comparably selected and treated patients with unstable angina or non-ST-segment elevation myocardial infarction. TIMI 3B further compared management with early cardiac catheterization (and percutaneous transluminal coronary angioplasty or coronary artery bypass surgery, if appropriate) at 18 to 48 hours (h) after presentation (Invasive Strategy), versus angiography with revascularization only if the patient had spontaneous or provokable ischemia (Conservative Strategy). The TIMI 3A study recruited participants aged 21 to 76 y, and TIMI 3B aged 21 to 79 y, in respectively 15 and 25 participating centers across the United States of America and Canada. All patients had given written informed consent to participate in the study.^9,10 Patients were required to have chest discomfort at rest suggestive of myocardial ischemia, lasting greater than 5 minutes but less than 6 hours, which occurred within 12 hours (24 hours for TIMI 3B) of the time of enrollment. Not eligible for inclusion were patients who underwent bypass surgery, had experienced MI within the preceding 21 days (excluding within 12 hours before enrollment), had new, persistent ST-segment elevation, had PTCA in the past 6 months, had contraindication for thrombolytic therapy, used oral anticoagulant therapy, had any history of cerebrovascular disease or transient ischemic attack, or advanced illness including malignancies, hepatic, renal disorders, among other criteria. Standard clinical care included heparin given as a bolus of 5000 IU iv followed by an infusion of 1000 IU/h to reach aPTT 1.5 to 2.0 times normal, and anti-ischemic therapy with a beta-adrenergic blocker, a calcium channel blocker, and a nitrate preparation. Aspirin was not given routinely in TIMI 3A and 325 mg daily from Day 2 in TIMI 3B. The primary comparison was rt-PA vs. placebo (blinded), with a primary end point of improvement in perfusion or stenosis in TIMI 3A. In TIMI 3B, the secondary comparison was Invasive vs. Conservative Strategy (unblinded), with a combined primary endpoint of reduction in death, (subsequent) myocardial infarction, or either spontaneous or provokable ischemia within or at 6 weeks after study drug infusion. The main secondary evaluation was at Day 21 after submission.^9,10

Prevention and Management of Hemorrhagic Complications

Taken the high bleeding rate in the TIMI 2 trial into account (investigator-reported bleeding in 58.4% of the patients),^6,11 elaborate measures were taken in TIMI 3 to prevent and treat hemorrhage, such as more stringent contraindications for thrombolytic therapy compared to TIMI 2.^6,9-11 While in TIMI 2, 100 to 150 mg rt-PA was used, rt-PA dose was reduced in TIMI 3 to 0.8 mg/kg, with a maximum of 80 mg. aPTT-guided heparin dose adjustments were part of the study protocol, and relating to the high number of puncture bleeds in TIMI 2,^6,11 heparin doses were routinely reduced 4 hours prior to the first arterial puncture for the arteriogram. Major vascular catheter entry sites were minimized and protected with sheath-introducers to tamponade the site for approximately 24 hours. Vascular puncture sites were treated with compression dressings, and sites of vascular entry were checked every two hours during the acute study period. Other measures included complete blood count at least every 12 hours during the first 24 hours after the intervention, and testing of stool, urine and vomitus specimens for occult blood. Frequent clinical assessments and examinations were advised to assess potential internal hemorrhage. If bleeding occurred, management was highly protocolized, and specific therapy was given according to site of bleeding, such as antacids and histamine 2 receptor blockers for upper gastrointestinal bleeding. Finally, life-threatening hemorrhagic complications or any were reported immediately to the Coordinating Center and the Program Office.^9,10

Classification of Hemorrhagic Events

Bleeding was classified by the Hemorrhagic Event Review Committee as described previously,¹¹ as “major” when a decrease in hemoglobin of >50 g/L (>3.1 mmol/L), intracranial bleeding, or cardiac tamponade was present, or with death from hemorrhage; as “minor” if a hemoglobin reduction 30 to 50 g/L (1.9 to 3.1 mmol/L) from an identified bleeding site was present, or if the patient had spontaneous macroscopic hematuria, hemoptysis, or hematemesis; and as “loss-no-site” if the bleeding site was unknown, but hemoglobin reduction was 40 to 50 g/L (2.5 to 3.1 mmol/L). Transfusion of one unit of packed cells or whole blood was counted as 10 g/L or hematocrit reduction of 3%.^9-11

Laboratory studies

Total CK activity was estimated at the study centers, collected at baseline (pre-treatment), during the first 3 days, at 4, 12, 24, 48, and 72 hours, and thereafter when indicated. The upper reference limit (URL) as defined by the local laboratory was recorded. CK twice the URL was considered evidence of infarction. Fibrinogen levels and fibrin(ogen) degradation products, were collected at baseline (pre-treatment), and at 50 min, and at 12, 24, 48, 96 hours after rt-PA infusion, and determined in a central Coagulation Core Laboratory, using standardized methods as described previously.^9,10 Platelet count was determined locally at the participating centers.

Main outcomes

The main outcomes of this analysis are the independent association of peak CK activity with adjudicated major bleeding (primary); and with combined adjudicated major bleeding, stroke, and all-cause mortality (ACM) during hospitalization (secondary).

Sample size considerations

The probability P of events at the mean value of the CK (and other variables) was conservatively estimated to be 0.10. Based on the previous report,⁶ sample size was estimated for two levels of the OR of disease, corresponding to an increase of one standard deviation from the mean value of CK, given the mean values of the remaining variables; at OR 1.2, with at least 634 participants needed; or at OR 2.0, with at least 226 needed for this analysis with a one-tailed alpha of 5% and 1 – beta of 90. A second consideration was to include a minimum of 10 events of the least frequent outcome per parameter to fit the model to avoid over or under estimated variances.¹²

Data analyses

Data of the TIMI 3B study are analyzed. Demographic characteristics are reported by bleeding status. Parametric versus nonparametric statistical methods are used where appropriate. CK data are known to be highly skewed to the right and log transformation to the base of 10 is used in regression analysis.⁶ Mean as well as peak CK during admission are assessed (primary variable), as crude values, and standardized by the local upper reference limit (URL). In addition, time to CKmax, and time to, severity, and location of the first adjudicated bleeding are noted. Major bleeding is associated with CKmax presented in categories, and as a continuous measure in univariable and multivariable logistic regression analysis, to assess whether log CKmax is independently predictive of fatal or non-fatal major bleeding (primary), or combined major bleeding, stroke, and all-cause mortality (ACM, secondary), at Day 21 after hospital admission. Five covariables are chosen a priori, sex, age, body mass index (BMI, body weight in kg divided by the squared height in meters), history of diabetes, and systolic blood pressure (SBP) at admission. Other variables are considered based on statistical and clinical criteria and bleeding risk scores^1-6;,9-11 to find the most parsimonious model that explains the data, using forced entry and bootstrapping for internal validation. Global model fit is based on Bayes information criterion (BIC), and calibration included Hosmer-Lemeshow statistics. Main subgroup analysis is by rt-PA treatment assignment vs. placebo. Sensitivity analysis include modelling with different relevant covariables and by peak CK at 24h. Model discrimination is assessed with C-statistics.¹³ Missing data are not imputed, and p-values are not reported for study outcomes.¹⁴ Where relevant, statistical uncertainty surrounding the estimates is communicated through 95% confidence intervals (CI) given between square brackets, with uncertainty regarding the external validity discussed. Data in parentheses are SE unless indicated otherwise. Statistical analyses are performed with the SPSS statistical software package for Windows version 25.0 (SPSS Inc, Chicago, Ill, USA).

Baseline Characteristics and Assigned Treatment

TIMI 3B patients were predominantly men (66.3%) and white (79.7%), with a mean age of 58.8 (0.3) years (Table 1). Patients were randomized to rt-PA (49.4%) or placebo (50.6%), and to the invasive strategy (49.8%) vs. the conservative strategy (50.2%). Median duration of hospitalization was 11 days (interquartile range, IQR 7 to 14 days). During the first 5 days of hospitalization, nearly all patients were given heparin (99.7%) and aspirin (99.5%), with a median total daily dose (IQR) of 17 519 U USP (IQR 13 600 to 21 320) for heparin, and 260 mg (195 to 284) for aspirin.

Trial Outcomes

TIMI3 trial endpoints by treatment arm have been reported previously.^9,10 In summary, in TIMI 3A, of all culprit lesions, 25% with rt-PA vs. 19% with placebo achieved the primary endpoint of measurable improvement. A thrombus was present in the culprit lesion in 107 patients (35%), and in these patients, substantial improvement occurred in 36% of the patients with rt-PA vs. 15% with placebo. However, in the TIMI 3B study, the incidence of death or non-fatal infarction did not differ after one year by strategy assignment, although fewer patients in the early invasive strategy group underwent repeat hospital admission.^9,10

CK

CK was estimated at 18 different time points, in total 9 215 times in 1 470 patients during the hospital stay, from the day of admission to day 17. Plasma CK, missing in 4 patients, ranged between <10 to 19 045 IU/L. Mean CK per patient was 221(9) IU/L, with a mean URL of 212 IU/L. CKmax ranged between 15 and 19 045 IU/L (mean 450(24); median 152, IQR 82 to 433), a mean of 2.2(0.1) times the URL (Figure 2, Panel A and B). Most patients (58%) had a peak CK level below the URL, and only 25% of the patients had a CK greater than twice normal; with the highest CK activity on the first day in most patients (Figure 2. Panel C).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 2. The Association between CK and Bleeding

The association between creatine kinase (CK) and bleeding. Panel A (IU/L) and B (CK normalized for the upper reference limit, URL) show CK activity below URL in the majority of patients, as expected with non-ST-segment elevation acute coronary syndromes. Panel C and D depict the time to peak CK value (day 1) vs. time to the first adjudicated bleeding (peak at Day2). Panel E shows the site and severity of adjudicated bleeding (with surgical bleeding classified as “other”), and Panel G and H the primary and secondary outcome by CK level, with crude CK levels and in univariable and multivariable logistic regression analysis by CK adjusted for URL (panel H). GU, RP, IC, GI, PS, U/O are respectively, genitourinary, retroperitoneal, intracranial, gastrointestinal, puncture site (vascular access site-related), or unknown/other.

Panel A-B. Peak plasma CK activity

Panel C-D. Timing of peak CK and bleeding

Panel E-F. Bleeding events by Site and CK

Panel G-H. Composite outcomes by CK (Univariable and Multivariable)

Hemorrhagic complications

Bleeding, reported in 128 patients (8.7%), was most frequent on the second day after admission (24.2%, Figure 2, Panel D). Adjudicated bleeding events were registered in 90 patients, 30 (33.3%) with major bleeding, 43 (41.1%) minor bleeding, and 23 (25.6%) loss-no-site. Primary bleeding locations are depicted by severity in Figure 2, Panel E, with surgery-related bleeding (11 patients) classified as “other”. Stroke (hemorrhagic and non-hemorrhagic) was reported in 18 patients. Thirty patients died during hospitalization (2.1%), of whom 9 (30%) had a major bleeding or stroke. Seven out of 30 patients (23.3%) with a major bleeding died, and 64 patients (4.3%) had a major bleeding, stroke or ACM.

Mean CKmax in patients without major bleeding was 439(23) IU/L, (2.2*URL, SE 0.1), vs 1 015(319) IU/L, (5.6*URL, SE 2.4) with major bleeding. The association between CK and major bleeding included “normal” CK levels (Figure 2, Panel F and G). In univariable binary logistic regression analysis, the OR of fatal or non-fatal major bleeding was 3.2 [1.7 to 6.0]/log CKmax increase. For the composite outcome major bleeding, stroke, or hospital death, mean CKmax was 1 177(231), (6.1*URL, SE 1.5); mean age 64(1.0) years, OR 3.6 [2.3 to 5.7]. Sex, age, ancestry (white vs. non-white), BMI, a history of diabetes or hypertension, baseline SBP, baseline laboratory values (e.g. hematocrit, creatinine, platelet count), and treatment assignment (conservative vs. invasive and rt-PA vs. placebo), were further considered as predictors of the main primary and secondary outcomes. Data on congestive heart failure and heart rate at admission were not available. Multivariable binary logistic regression analysis suggested an independent association between peak CK and major bleeding as well as the composite outcome, with per log CK increase a 3-fold increase in odds for non-fatal or fatal major bleeding and a nearly 4-fold increase in combined major bleeding, stroke, or ACM, compared to the absence of these outcomes (Table 2 A and B; and Figure 2 Panel H). The C-index of the final models was 0.8 (Figure 3). Although the number of events in the subgroups were too small to build a stable statistical model, the data indicated that the association between CK and major bleeding was similar in size and direction in patients who received placebo (respectively 6.12 [1.70 to 21.99], n=703); vs. rt-PA 2.27 [1.08 to 4.77], n=667).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 3.

C-indices of covariables and final logistic regression models. AUC, area under the curve; CK, creatine kinase; rt-PA, recombinant tissue-type plasminogen activator use; parameter units are as in Table 1.

Panel A. C-index CK and Major Bleeding

Panel B. C-index CK and Major Bleeding, Stroke or all-cause mortality